

Oral Presentations at ASH Annual Meeting

All times listed are Eastern Time. Schedule and locations subject to change by ASH.

PRESENTATION	SPEAKER	TIME/LOCATION
Saturday, December 6, 2025		
Meet the Journal Editors: <i>Blood Immunology & Cellular Therapy</i>	Caron Jacobson, MD, MMSc	8:30 a.m. West Halls B3-B4 (Orange County Convention Center)
85: Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB16673 in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the ongoing phase 1 CaDAnCe-101 study	Inhye Ahn, MD	9:30 a.m. W224ABEF (Orange County Convention Center)
8: Sickle cell disease is associated with early-onset clonal hematopoiesis involving DNA damage response pathway mutations	Lachelle Weeks, MD, PhD	9:30 a.m. W311ABCD (Orange County Convention Center)
53: Functional investigation into NK cells identifies salt-inducible kinases as novel therapeutic targets against NK malignancies	Arindam Ray, PhD	10:30 a.m. Tangerine Ballroom F1 (Orange County Convention Center)
235: Subgroup analyses from the randomized, phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk myelodysplastic syndromes (HR MDS)	Guillermo Garcia-Manero, MD	2:00 p.m. Valencia Room W415BC (Orange County Convention Center)
Education Program: Could Treatment Modification Based on Early Response Assessment Improve Results in DLBCL?	Jennifer Crombie, MD	2:00 p.m. Tangerine Ballroom F1 (Orange County Convention Center)
224: Double-hit alterations of TP53 identify ultra high-risk disease in previously treated, MYD88 mutated Waldenström macroglobulinemia	Nickolas Tsakmaklis	2:15 p.m. Tangerine Ballroom F2 (Orange County Convention Center)
225: High VGPR/CR rates with pirtobrutinib plus venetoclax in previously treated Waldenström macroglobulinemia: Results from a multicenter phase II study	Jorge Castillo, MD	2:30 p.m. Tangerine Ballroom F2 (Orange County Convention Center)

Oral Presentations at ASH Annual Meeting

All times listed are Eastern Time. Schedule and locations subject to change by ASH.

PRESENTATION	SPEAKER	TIME/LOCATION
Saturday, December 6, 2025		
261: In depth characterization of autologous infused bhv-1100 armored memory-like NK cells in MRD+ multiple myeloma patients receiving autologous stem cell transplant	Grace Birch, PhD	2:30 p.m. Chapin Theater (W320) (Orange County Convention Center)
285: Medicaid versus commercial insurance: Association with quality of end-of-life care among patients with blood cancers	Hari Raman, MD, MBA	2:30 p.m. W224ABEF (Orange County Convention Center)
274: Primary results from Equator, a phase 3 double-blind, randomized placebo-controlled study evaluating itolizumab in combination with corticosteroids as initial treatment of acute graft-versus-host disease	John Koreth, MD, MBBS, PhD, DPhil	2:45 p.m. W331 (Orange County Convention Center)
215: An actionable DNA repair defect in myeloid malignancies with U2AF1 S34 mutations	Shuhe Asada, MD, PhD	3:00 p.m. W414CD (Orange County Convention Center)
245: Distinct archetypes of clonal dynamics underlie response and resistance to diverse CLL therapies	Marwan Kwok, MD, PhD	3:00 p.m. W224CDGH (Orange County Convention Center)
246: A tandem CD19/ROR1 CAR-NK to overcome Wnt5a-mediated apoptotic resistance in chronic lymphocytic leukemia	Salem Elias, MD	3:15 p.m. W224CDGH (Orange County Convention Center)
264: LIME: A first-in-class of live bacterial immune engagers for cancer immunotherapy	Anna Clara Bader	3:15 p.m. Chapin Theater (W320) (Orange County Convention Center)
349: Relapsed diffuse large B-cell lymphoma is shaped by molecular subtypes and genomic alterations	Eleonora Calabretta, MD	4:00 p.m. Tangerine Ballroom F1 (Orange County Convention Center)

Oral Presentations at ASH Annual Meeting

All times listed are Eastern Time. Schedule and locations subject to change by ASH.

PRESENTATION	SPEAKER	TIME/LOCATION
Saturday, December 6, 2025		
373: Longer telomeres in donors aged ≥35 years reduce graft failure and non-relapse mortality after allogeneic HCT	Nico Gagelmann, MD	4:00 p.m. Sunburst Room (W340) (Orange County Convention Center)
403: Results of the promise study from ~30,000 individuals screened for monoclonal gammopathies	Sabine Allam, MD	4:00 p.m. West Hall E2 (Orange County Convention Center)
Scientific Program: Beyond Malignancy: How Insights from IBMFS Inform Clonal Hematopoiesis Malignancy Risk More Broadly	R. Coleman Lindsley, MD, PhD	4:20 p.m. Plaza Int'l HIJK (Hyatt)
327: Functional genomics studies identify determinants of response vs. resistance to pharmacological inhibitors of KRAS in multiple myeloma	Torsten Steinbrunn, MD, PhD	4:30 p.m. W230 (Orange County Convention Center)
351: Circulating tumor DNA analyses of molecular tumor burden are superior to PET- assessed responses in patients with advanced stage classic Hodgkin lymphoma treated on SWOG S1826	Julia Paczkowska, PhD	4:30 p.m. Tangerine Ballroom F1 (Orange County Convention Center)
Education Program: When Immature Plasma Cells Form Lymphoma: How to Improve on Diagnostics and Treatment of Plasmablastic Lymphoma?	Jorge Castillo, MD	4:40 p.m. Tangerine Ballroom F2 (Orange County Convention Center)
329: Molecular and functional determinants of response to venetoclax and inotuzumab ozogamicin in CD22-positive ALL	Mark Murakami, MD	5:00 p.m. W230 (Orange County Convention Center)